Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

93839

registered interest
date	16/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mental Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what National Institute for Health and Care Excellence-approved interventions are available through the NHS for the treatment of mental health conditions.
tabling member constituency	East Worthing and Shoreham
tabling member printed	Tim Loughton
uin	210896
answer	answer is ministerial correction date of answer 21/10/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) has published clinical guidelines on a range of mental health topics, such as depression, anxiety and schizophrenia. Clinical guidelines provide guidance on the treatment of patients across the care pathway and each guideline recommends a number of treatments.<br> <br> Additionally, the following technologies for the treatment of mental health and behavioural conditions are recommended by NICE technology appraisal guidance:</p><p> </p><table><tbody><tr><td><p>Appraisal Number</p></td><td><p>Year</p></td><td><p>Technology</p></td><td><p>Condition</p></td><td><p>Categorisation</p></td></tr><tr><td><p>TA59</p></td><td><p>2003</p></td><td><p>Electroconvulsive therapy</p></td><td><p>Catatonia/ prolonged or severe manic episode</p></td><td><p>Optimised<sup>1</sup></p></td></tr><tr><td><p>TA098</p></td><td><p>2006</p></td><td><p>Atomoxetine</p></td><td><p>Attention deficit hyperactivity disorder (ADHD)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA098</p></td><td><p>2006</p></td><td><p>Dexamfetamine</p></td><td><p>Attention deficit hyperactivity disorder (ADHD)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA098</p></td><td><p>2006</p></td><td><p>Methylphenidate</p></td><td><p>Attention deficit hyperactivity disorder (ADHD)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA213</p></td><td><p>2011</p></td><td><p>Aripiprazole</p></td><td><p>Schizophrenia in people aged 15-17 years</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Donepezil</p></td><td><p>Alzheimer's disease (mild to moderate)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Galantamine</p></td><td><p>Alzheimer's disease (mild to moderate)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Rivastigmine</p></td><td><p>Alzheimer's disease (mild to moderate)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Memantine</p></td><td><p>Alzheimer's disease (moderate)</p></td><td><p>Optimised</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Memantine</p></td><td><p>Alzheimer's disease (severe)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA292</p></td><td><p>2013</p></td><td><p>Aripiprazole</p></td><td><p>Moderate to severe manic episodes in adolescents with bipolar disorder</p></td><td><p>Recommended</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p><em>Source</em>: National Institute for Health and Care Excellence</p><p> </p><p> </p><p> </p><p><sup>1 </sup>The drug or technology is recommended for a smaller subset of patients than originally stated by the marketing authorisation.</p><p> </p><p> </p><p> </p><p>Patients have the right to drugs and treatments that have been recommended by NICE technology appraisal guidance for use in the National Health Service, where their doctor believes they are clinically appropriate.</p><p> </p><p> </p><p> </p><p>Details of all NICE’s guidance on mental health and behavioural conditions can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/guidancemenu/conditions-and-diseases/mental-health-and-behavioural-conditions" target="_blank">www.nice.org.uk/guidancemenu/conditions-and-diseases/mental-health-and-behavioural-conditions</a></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/10/2014 15:12:00 answering member 4020 label Biography information for George Freeman
tabling member	114 label Biography information for Tim Loughton

100022

registered interest
date	15/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Patient Choice Schemes
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to promote patient choice.
tabling member constituency	Stroud
tabling member printed	Neil Carmichael
uin	905559
answer	answer is ministerial correction date of answer 21/10/2014 answer text <p>We are committed to patients having greater choice and control over their healthcare, as this can help drive up standards and improve patient care.</p><p> </p><p> </p><p> </p><p>We believe that patient empowerment is vital to the National Health Service in the 21st century. This Government is committed to continuing to develop digital platforms to enable this to happen, such as My NHS and the NHS e-Referral Service.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/10/2014 16:00:56 answering member 4020 label Biography information for George Freeman
tabling member	4104 label Biography information for Neil Carmichael

93566

registered interest
date	15/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the value is of the rebate payments made by industry under the Pharmaceutical Price Regulation Scheme to date; and what proportion of that rebate has been reinvested in (i) healthcare services and (ii) medicines expenditure.
tabling member constituency	Cambridge
tabling member printed	Dr Julian Huppert
uin	210640
answer	answer is ministerial correction date of answer 20/10/2014 answer text <p>The Department has received £74 million from members of the Pharmaceutical Price Regulation Scheme (PPRS) in respect of PPRS payments for the first quarter of the calendar year 2014 and £76 million in respect of the second quarter. The Department will publish aggregate information on sales reports and payments made under the scheme on a quarterly basis. The first two quarters PPRS payments were published in June and September 2014 respectively and can be found on the Government’s website at:</p><p> </p><p> </p><p> </p><p><a href="https://www.gov.uk/government/publications/pprs-quarterly-net-sales-and-payment-information" target="_blank">https://www.gov.uk/government/publications/pprs-quarterly-net-sales-and-payment-information</a></p><p> </p><p> </p><p> </p><p>In respect of England, the anticipated payments in 2014-15 have been passed on to NHS England through the Mandate and as such were included within commissioner allocations.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/10/2014 16:15:30 answering member 4020 label Biography information for George Freeman
tabling member	3931 label Biography information for Dr Julian Huppert

93573

registered interest
date	15/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund: Liverpool
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what proportion of the cancer drugs fund has been spent in Liverpool since its inception.
tabling member constituency	Liverpool, Walton
tabling member printed	Steve Rotheram
uin	210689
answer	answer is ministerial correction date of answer 20/10/2014 answer text <p>Prior to April 2013, information on the Cancer Drugs Fund was administered through clinical panels based in each strategic health authority (SHA) and data on spend through the Fund in each city was not collected. Information on spend by the North West SHA and in England in 2010-11, 2011-12 and 2012-13 is shown in the following table:</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p> </p></td><td><p>Amount Spent (£000)</p><p>2010-11</p></td><td><p>Amount Spent (£000)<br> 2011-12</p></td><td><p>Amount Spent (£000)<br> 2012-13</p></td></tr><tr><td><p>North West SHA</p></td><td><p>7,400</p></td><td><p>10,015</p></td><td><p>29,272</p></td></tr><tr><td><p>England</p></td><td><p>38,254</p></td><td><p>108,327</p></td><td><p>175,334</p></td></tr></tbody></table><p> </p><p><em>Source</em>: Information provided to the Department by SHAs</p><p> </p><p> </p><p> </p><p>NHS England has had oversight of the Fund since April 2013 and does not collect information at city level. In 2013-14, £63,368,429 was spent through the Fund in the North of England region and total national expenditure in England, net of any central rebates, was £230,539,005. Figures for 2014-15 are not currently available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/10/2014 16:20:31 answering member 4020 label Biography information for George Freeman
tabling member	4035 label Biography information for Steve Rotheram

93283

registered interest
date	14/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Anticoagulants
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 12 July 2014 to Question 206057, on anticoagulants, what plans the National Institute for Health and Care Excellence has to update that guidance.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	210583
answer	answer is ministerial correction date of answer 17/10/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) regularly reviews the need to update its published guidance in order to take account of the latest available evidence.</p><p> </p><p> </p><p> </p><p>We understand that NICE considered updating its technology appraisal guidance on bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230) in 2012 and decided, following consultation with stakeholders, to incorporate the recommendations into its clinical guideline on myocardial infarction with ST-segment elevation (CG167). The guideline was published in July 2013 and NICE has advised that it will undergo a surveillance review two years after its publication, expected in July 2015.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 17/10/2014 12:35:32 answering member 4020 label Biography information for George Freeman
tabling member	4036 label Biography information for Luciana Berger

92828

registered interest
date	13/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 16 July 2014 to Question 204839, whether NHS England will publish the Innovation Health and Wealth refresh review before (a) 31 December 2014 and (b) 31 March 2015.
tabling member constituency	Ealing, Southall
tabling member printed	Mr Virendra Sharma
uin	210132
answer	answer is ministerial correction date of answer 20/10/2014 answer text <p>National Health Service England has advised that the publication of this review has been superseded by a five-year forward view of innovation, led by the national clinical director for innovation, which will be published shortly.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/10/2014 16:32:52 answering member 4020 label Biography information for George Freeman
tabling member	1604 label Biography information for Mr Virendra Sharma

92829

registered interest
date	13/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent discussions he has had with NHS England on assessment of dispensing appliance contractor licences on a national basis.
tabling member constituency	Ealing, Southall
tabling member printed	Mr Virendra Sharma
uin	210128
answer	answer is ministerial correction date of answer 20/10/2014 answer text <p>The Department sets the legislative framework for the inclusion of dispensing appliance contractors on National Health Service England pharmaceutical lists. It is up to NHS England to administer the Regulations and to monitor these contractors. It is for NHS England to approach the Department if they wish to discuss changes to the legislative arrangements. No such approach has been made.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/10/2014 16:34:38 answering member 4020 label Biography information for George Freeman
tabling member	1604 label Biography information for Mr Virendra Sharma

92830

registered interest
date	13/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Intellectual Property
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many items of intellectual property have been protected against exploitation; and what assessment he has made of the (a) financial and (b) other effects of the exploitation of intellectual property generated by National Institute of Health Research funding.
tabling member constituency	Ealing, Southall
tabling member printed	Mr Virendra Sharma
uin	210133
answer	answer is ministerial correction date of answer 20/10/2014 answer text <p>The Department’s National Institute for Health Research (NIHR) recognises the key role of Intellectual Property (IP) assets in driving innovation, and the importance of a range of associated activities such as fostering a culture of invention through to collaborating with industry. The NIHR standard research contract is worded to ensure appropriate exploitation of IP.</p><p> </p><p> </p><p> </p><p>For 2013-14, NIHR biomedical research centres and units reported a total of 98 patent applications granted, 106 licensing deals agreed, and 6 spin-off companies established.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/10/2014 16:50:17 answering member 4020 label Biography information for George Freeman
tabling member	1604 label Biography information for Mr Virendra Sharma

92833

registered interest
date	13/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the Answer of 26 March 2013 to Question 149577, where the minutes of his regular formal accountability meetings with the Chair of the Board are published; and how he holds the Board to account to meet its duties to promote (a) the commercialisation of intellectual property and (b) other forms of innovation.
tabling member constituency	Ealing, Southall
tabling member printed	Mr Virendra Sharma
uin	210131
answer	answer is ministerial correction date of answer 20/10/2014 answer text <p>The Health and Social Care Act 2012 imposes a legal duty on the National Health Service Commissioning Board, known as NHS England, to promote innovation. No such duty exists to promote the commercialisation of intellectual property.</p><p> </p><p><strong> </strong></p><p> </p><p>The Secretary of State holds NHS England to account for delivery of its mandate objectives and legal duties through bi-monthly accountability meetings. These feed into an annual assessment of NHS England, which is laid before Parliament. The “Annual Assessment of the NHS Commissioning Board (known as NHS England) 2013-14” was laid in Parliament on 22 July 2014 and included an assessment of NHS England’s performance on innovation.</p><p> </p><p> </p><p> </p><p>The minutes of the regular formal accountability meetings between the Secretary of State and the Chair of the NHS Commissioning Board (the legal name for NHS England) are published online on the Government website:</p><p> </p><p> </p><p> </p><p>https://www.gov.uk/government/publications/nhs-commissioning-board-accountability-meeting-minutes</p><p> </p><p> </p><p> </p><p>Ministers and officials also regularly meet with NHS England to discuss a range of subjects.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/10/2014 16:26:23 answering member 4020 label Biography information for George Freeman
tabling member	1604 label Biography information for Mr Virendra Sharma

92834

registered interest
date	13/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Intellectual Property
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether the new Academic Health Science Networks contract with NHS England includes responsibility for identification, protection and exploitation of intellectual property support for local NHS organisations.
tabling member constituency	Ealing, Southall
tabling member printed	Mr Virendra Sharma
uin	210124
answer	answer is ministerial correction date of answer 20/10/2014 answer text <p>Although Academic Health Science Networks (AHSNs) may offer support to National Health Service organisations in identification, protection and exploitation of intellectual property, it is not an explicit requirement of the contract that they do so. <br> <br> AHSNs are responsible for identifying local priorities for driving patient-based research, improvement pathway, inward investment and life science income based upon local need and by drawing upon local opportunities, resources and expertise within their networks. It is for AHSNs to determine how they can best deliver upon these objectives.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 20/10/2014 16:23:47 answering member 4020 label Biography information for George Freeman
tabling member	1604 label Biography information for Mr Virendra Sharma